Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis
Background We aimed to elucidate the relationship between serum myostatin levels and other markers including skeletal muscle mass and to investigate the influence of serum myostatin levels on survival for patients with liver cirrhosis (LC). Methods A total of 198 LC subjects were analysed in this st...
Gespeichert in:
| Veröffentlicht in: | Journal of cachexia, sarcopenia and muscle sarcopenia and muscle, 2017-12, Vol.8 (6), p.915-925 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 925 |
|---|---|
| container_issue | 6 |
| container_start_page | 915 |
| container_title | Journal of cachexia, sarcopenia and muscle |
| container_volume | 8 |
| creator | Nishikawa, Hiroki Enomoto, Hirayuki Ishii, Akio Iwata, Yoshinori Miyamoto, Yuho Ishii, Noriko Yuri, Yukihisa Hasegawa, Kunihiro Nakano, Chikage Nishimura, Takashi Yoh, Kazunori Aizawa, Nobuhiro Sakai, Yoshiyuki Ikeda, Naoto Takashima, Tomoyuki Takata, Ryo Iijima, Hiroko Nishiguchi, Shuhei |
| description | Background
We aimed to elucidate the relationship between serum myostatin levels and other markers including skeletal muscle mass and to investigate the influence of serum myostatin levels on survival for patients with liver cirrhosis (LC).
Methods
A total of 198 LC subjects were analysed in this study. Myostatin levels were measured using stored sera. We retrospectively investigated the relationship between myostatin level and other markers, and the influence of myostatin level on overall survival (OS). Assessment of skeletal muscle mass was performed using the psoas muscle index (PMI) on computed tomography images at baseline. PMI indicates the sum of bilateral psoas muscle mass calculated by hand tracing at the lumber three level on computed tomography images divided by height squared (cm2/m2). The study cohort was divided into two groups based on the median myostatin value in each gender.
Results
Our study cohort included 108 male and 90 female patients with a median age of 67.5 years. The median (range) myostatin level for male patients was 3419.6 pg/mL (578.4–12897.7 pg/mL), whereas that for female patients was 2662.4 pg/mL (710.4–8782.0 pg/mL) (P = 0.0024). Median (range) serum myostatin level for Child–Pugh A patients (n = 123) was 2726.0 pg/mL (578.4–12667.2 pg/mL), whereas that for Child–Pugh B or C patients (n = 75) was 3615.2 pg/mL (663.3–12897.7 pg/mL) (P = 0.0011). For the entire cohort, the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 93.94%, 72.71%, 50.37%, and 38.47%, respectively, in the high‐myostatin group and 96.97%, 83.27%, 73.60%, and 69.95%, respectively, in the low‐myostatin group (P = 0.0001). After excluding hepatocellular carcinoma patients (at baseline) from our analysis (n = 158), the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 96.0%, 77.93%, 52.97%, and 39.08%, respectively, in the high‐myostatin group and 96.39%, 87.58%, 77.63%, and 73.24%, respectively, in the low‐myostatin group (P = 0.0005). Higher age (P = 0.0111) and lower PMI (P |
| doi_str_mv | 10.1002/jcsm.12212 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5700437</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2289813310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4762-b29bee6ef775d4ccb4eb0edd655271219062b348d3c1046c5600c30a4643718e3</originalsourceid><addsrcrecordid>eNp9kUtr3DAUhUVpaUKSTX9AEXRTApPoYUv2plCGPEnJIu1ayPKdjgbbmujaHubfRxNPQppFtZHQ_XQ4R4eQL5ydccbE-cphe8aF4OIDORS8ZDPFWPlxf87Lkh-QE8QVSytTXOXsMzkQhRKaCX1I7EUDo-2hpghxaGm7Ddjb3nc03UNDPVKLGJx_Zja-X9JNiAgUhzj60Saio-v0ALoep3njR4jU-RiXAT0ek08L2yCc7Pcj8ufy4vf8enZ3f3Uz_3k3c5lWYlaJsgJQsNA6rzPnqgwqBnWt8lxovgujRCWzopaOpyAuTzGdZDZTmdS8AHlEfky666FqoXbJULSNWUff2rg1wXrz76TzS_M3jCbX6WekTgLf9wIxPA6AvWk9Omga20EY0PCSc8G0FGVCv71DV2GIXYpnhCjKgkvJWaJOJ8rFgBhh8WqGM7Mrz-zKM8_lJfjrW_uv6EtVCeATsPENbP8jZW7nD78m0Sfrx6XH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2289813310</pqid></control><display><type>article</type><title>Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Nishikawa, Hiroki ; Enomoto, Hirayuki ; Ishii, Akio ; Iwata, Yoshinori ; Miyamoto, Yuho ; Ishii, Noriko ; Yuri, Yukihisa ; Hasegawa, Kunihiro ; Nakano, Chikage ; Nishimura, Takashi ; Yoh, Kazunori ; Aizawa, Nobuhiro ; Sakai, Yoshiyuki ; Ikeda, Naoto ; Takashima, Tomoyuki ; Takata, Ryo ; Iijima, Hiroko ; Nishiguchi, Shuhei</creator><creatorcontrib>Nishikawa, Hiroki ; Enomoto, Hirayuki ; Ishii, Akio ; Iwata, Yoshinori ; Miyamoto, Yuho ; Ishii, Noriko ; Yuri, Yukihisa ; Hasegawa, Kunihiro ; Nakano, Chikage ; Nishimura, Takashi ; Yoh, Kazunori ; Aizawa, Nobuhiro ; Sakai, Yoshiyuki ; Ikeda, Naoto ; Takashima, Tomoyuki ; Takata, Ryo ; Iijima, Hiroko ; Nishiguchi, Shuhei</creatorcontrib><description>Background
We aimed to elucidate the relationship between serum myostatin levels and other markers including skeletal muscle mass and to investigate the influence of serum myostatin levels on survival for patients with liver cirrhosis (LC).
Methods
A total of 198 LC subjects were analysed in this study. Myostatin levels were measured using stored sera. We retrospectively investigated the relationship between myostatin level and other markers, and the influence of myostatin level on overall survival (OS). Assessment of skeletal muscle mass was performed using the psoas muscle index (PMI) on computed tomography images at baseline. PMI indicates the sum of bilateral psoas muscle mass calculated by hand tracing at the lumber three level on computed tomography images divided by height squared (cm2/m2). The study cohort was divided into two groups based on the median myostatin value in each gender.
Results
Our study cohort included 108 male and 90 female patients with a median age of 67.5 years. The median (range) myostatin level for male patients was 3419.6 pg/mL (578.4–12897.7 pg/mL), whereas that for female patients was 2662.4 pg/mL (710.4–8782.0 pg/mL) (P = 0.0024). Median (range) serum myostatin level for Child–Pugh A patients (n = 123) was 2726.0 pg/mL (578.4–12667.2 pg/mL), whereas that for Child–Pugh B or C patients (n = 75) was 3615.2 pg/mL (663.3–12897.7 pg/mL) (P = 0.0011). For the entire cohort, the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 93.94%, 72.71%, 50.37%, and 38.47%, respectively, in the high‐myostatin group and 96.97%, 83.27%, 73.60%, and 69.95%, respectively, in the low‐myostatin group (P = 0.0001). After excluding hepatocellular carcinoma patients (at baseline) from our analysis (n = 158), the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 96.0%, 77.93%, 52.97%, and 39.08%, respectively, in the high‐myostatin group and 96.39%, 87.58%, 77.63%, and 73.24%, respectively, in the low‐myostatin group (P = 0.0005). Higher age (P = 0.0111) and lower PMI (P < 0.0001) were identified as significant predictors of poorer OS in our multivariate analysis, while higher serum myostatin (P = 0.0855) tended to be a significant adverse predictor. In both genders, PMI, serum albumin, prothrombin time, and branched‐chain amino acid to tyrosine ratio showed a significantly inverse correlation with myostatin levels, and serum ammonia levels showed a significantly positive correlation with myostatin levels.
Conclusions
Higher serum myostatin levels correlated with muscle mass loss, hyperammonemia, and impaired protein synthesis, as reflected by lower serum albumin levels and lower branched‐chain amino acid to tyrosine ratio levels. High serum myostatin levels were also associated with a reduced OS rate in LC patients.</description><identifier>ISSN: 2190-5991</identifier><identifier>EISSN: 2190-6009</identifier><identifier>DOI: 10.1002/jcsm.12212</identifier><identifier>PMID: 28627027</identifier><language>eng</language><publisher>Germany: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Body mass index ; Cause of Death ; Clinical outcomes ; Female ; Humans ; Insulin ; Kaplan-Meier Estimate ; Liver cancer ; Liver cirrhosis ; Liver Cirrhosis - blood ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - mortality ; Liver diseases ; Male ; Medical prognosis ; Metabolic disorders ; Middle Aged ; Muscle, Skeletal - metabolism ; Muscle, Skeletal - pathology ; Musculoskeletal system ; Myostatin - blood ; NMR ; Nuclear magnetic resonance ; Original ; Predictor ; Prognosis ; Proportional Hazards Models ; Protein synthesis ; Proteins ; Retrospective Studies ; Sarcopenia ; Serum myostatin ; Skeletal muscle ; Studies ; Ultrasonic imaging ; Young Adult</subject><ispartof>Journal of cachexia, sarcopenia and muscle, 2017-12, Vol.8 (6), p.915-925</ispartof><rights>2017 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders</rights><rights>2017 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders.</rights><rights>2017. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4762-b29bee6ef775d4ccb4eb0edd655271219062b348d3c1046c5600c30a4643718e3</citedby><cites>FETCH-LOGICAL-c4762-b29bee6ef775d4ccb4eb0edd655271219062b348d3c1046c5600c30a4643718e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700437/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700437/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28627027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nishikawa, Hiroki</creatorcontrib><creatorcontrib>Enomoto, Hirayuki</creatorcontrib><creatorcontrib>Ishii, Akio</creatorcontrib><creatorcontrib>Iwata, Yoshinori</creatorcontrib><creatorcontrib>Miyamoto, Yuho</creatorcontrib><creatorcontrib>Ishii, Noriko</creatorcontrib><creatorcontrib>Yuri, Yukihisa</creatorcontrib><creatorcontrib>Hasegawa, Kunihiro</creatorcontrib><creatorcontrib>Nakano, Chikage</creatorcontrib><creatorcontrib>Nishimura, Takashi</creatorcontrib><creatorcontrib>Yoh, Kazunori</creatorcontrib><creatorcontrib>Aizawa, Nobuhiro</creatorcontrib><creatorcontrib>Sakai, Yoshiyuki</creatorcontrib><creatorcontrib>Ikeda, Naoto</creatorcontrib><creatorcontrib>Takashima, Tomoyuki</creatorcontrib><creatorcontrib>Takata, Ryo</creatorcontrib><creatorcontrib>Iijima, Hiroko</creatorcontrib><creatorcontrib>Nishiguchi, Shuhei</creatorcontrib><title>Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis</title><title>Journal of cachexia, sarcopenia and muscle</title><addtitle>J Cachexia Sarcopenia Muscle</addtitle><description>Background
We aimed to elucidate the relationship between serum myostatin levels and other markers including skeletal muscle mass and to investigate the influence of serum myostatin levels on survival for patients with liver cirrhosis (LC).
Methods
A total of 198 LC subjects were analysed in this study. Myostatin levels were measured using stored sera. We retrospectively investigated the relationship between myostatin level and other markers, and the influence of myostatin level on overall survival (OS). Assessment of skeletal muscle mass was performed using the psoas muscle index (PMI) on computed tomography images at baseline. PMI indicates the sum of bilateral psoas muscle mass calculated by hand tracing at the lumber three level on computed tomography images divided by height squared (cm2/m2). The study cohort was divided into two groups based on the median myostatin value in each gender.
Results
Our study cohort included 108 male and 90 female patients with a median age of 67.5 years. The median (range) myostatin level for male patients was 3419.6 pg/mL (578.4–12897.7 pg/mL), whereas that for female patients was 2662.4 pg/mL (710.4–8782.0 pg/mL) (P = 0.0024). Median (range) serum myostatin level for Child–Pugh A patients (n = 123) was 2726.0 pg/mL (578.4–12667.2 pg/mL), whereas that for Child–Pugh B or C patients (n = 75) was 3615.2 pg/mL (663.3–12897.7 pg/mL) (P = 0.0011). For the entire cohort, the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 93.94%, 72.71%, 50.37%, and 38.47%, respectively, in the high‐myostatin group and 96.97%, 83.27%, 73.60%, and 69.95%, respectively, in the low‐myostatin group (P = 0.0001). After excluding hepatocellular carcinoma patients (at baseline) from our analysis (n = 158), the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 96.0%, 77.93%, 52.97%, and 39.08%, respectively, in the high‐myostatin group and 96.39%, 87.58%, 77.63%, and 73.24%, respectively, in the low‐myostatin group (P = 0.0005). Higher age (P = 0.0111) and lower PMI (P < 0.0001) were identified as significant predictors of poorer OS in our multivariate analysis, while higher serum myostatin (P = 0.0855) tended to be a significant adverse predictor. In both genders, PMI, serum albumin, prothrombin time, and branched‐chain amino acid to tyrosine ratio showed a significantly inverse correlation with myostatin levels, and serum ammonia levels showed a significantly positive correlation with myostatin levels.
Conclusions
Higher serum myostatin levels correlated with muscle mass loss, hyperammonemia, and impaired protein synthesis, as reflected by lower serum albumin levels and lower branched‐chain amino acid to tyrosine ratio levels. High serum myostatin levels were also associated with a reduced OS rate in LC patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers</subject><subject>Body mass index</subject><subject>Cause of Death</subject><subject>Clinical outcomes</subject><subject>Female</subject><subject>Humans</subject><subject>Insulin</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - blood</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - mortality</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metabolic disorders</subject><subject>Middle Aged</subject><subject>Muscle, Skeletal - metabolism</subject><subject>Muscle, Skeletal - pathology</subject><subject>Musculoskeletal system</subject><subject>Myostatin - blood</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Original</subject><subject>Predictor</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Protein synthesis</subject><subject>Proteins</subject><subject>Retrospective Studies</subject><subject>Sarcopenia</subject><subject>Serum myostatin</subject><subject>Skeletal muscle</subject><subject>Studies</subject><subject>Ultrasonic imaging</subject><subject>Young Adult</subject><issn>2190-5991</issn><issn>2190-6009</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtr3DAUhUVpaUKSTX9AEXRTApPoYUv2plCGPEnJIu1ayPKdjgbbmujaHubfRxNPQppFtZHQ_XQ4R4eQL5ydccbE-cphe8aF4OIDORS8ZDPFWPlxf87Lkh-QE8QVSytTXOXsMzkQhRKaCX1I7EUDo-2hpghxaGm7Ddjb3nc03UNDPVKLGJx_Zja-X9JNiAgUhzj60Saio-v0ALoep3njR4jU-RiXAT0ek08L2yCc7Pcj8ufy4vf8enZ3f3Uz_3k3c5lWYlaJsgJQsNA6rzPnqgwqBnWt8lxovgujRCWzopaOpyAuTzGdZDZTmdS8AHlEfky666FqoXbJULSNWUff2rg1wXrz76TzS_M3jCbX6WekTgLf9wIxPA6AvWk9Omga20EY0PCSc8G0FGVCv71DV2GIXYpnhCjKgkvJWaJOJ8rFgBhh8WqGM7Mrz-zKM8_lJfjrW_uv6EtVCeATsPENbP8jZW7nD78m0Sfrx6XH</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Nishikawa, Hiroki</creator><creator>Enomoto, Hirayuki</creator><creator>Ishii, Akio</creator><creator>Iwata, Yoshinori</creator><creator>Miyamoto, Yuho</creator><creator>Ishii, Noriko</creator><creator>Yuri, Yukihisa</creator><creator>Hasegawa, Kunihiro</creator><creator>Nakano, Chikage</creator><creator>Nishimura, Takashi</creator><creator>Yoh, Kazunori</creator><creator>Aizawa, Nobuhiro</creator><creator>Sakai, Yoshiyuki</creator><creator>Ikeda, Naoto</creator><creator>Takashima, Tomoyuki</creator><creator>Takata, Ryo</creator><creator>Iijima, Hiroko</creator><creator>Nishiguchi, Shuhei</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201712</creationdate><title>Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis</title><author>Nishikawa, Hiroki ; Enomoto, Hirayuki ; Ishii, Akio ; Iwata, Yoshinori ; Miyamoto, Yuho ; Ishii, Noriko ; Yuri, Yukihisa ; Hasegawa, Kunihiro ; Nakano, Chikage ; Nishimura, Takashi ; Yoh, Kazunori ; Aizawa, Nobuhiro ; Sakai, Yoshiyuki ; Ikeda, Naoto ; Takashima, Tomoyuki ; Takata, Ryo ; Iijima, Hiroko ; Nishiguchi, Shuhei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4762-b29bee6ef775d4ccb4eb0edd655271219062b348d3c1046c5600c30a4643718e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers</topic><topic>Body mass index</topic><topic>Cause of Death</topic><topic>Clinical outcomes</topic><topic>Female</topic><topic>Humans</topic><topic>Insulin</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - blood</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - mortality</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metabolic disorders</topic><topic>Middle Aged</topic><topic>Muscle, Skeletal - metabolism</topic><topic>Muscle, Skeletal - pathology</topic><topic>Musculoskeletal system</topic><topic>Myostatin - blood</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Original</topic><topic>Predictor</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Protein synthesis</topic><topic>Proteins</topic><topic>Retrospective Studies</topic><topic>Sarcopenia</topic><topic>Serum myostatin</topic><topic>Skeletal muscle</topic><topic>Studies</topic><topic>Ultrasonic imaging</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nishikawa, Hiroki</creatorcontrib><creatorcontrib>Enomoto, Hirayuki</creatorcontrib><creatorcontrib>Ishii, Akio</creatorcontrib><creatorcontrib>Iwata, Yoshinori</creatorcontrib><creatorcontrib>Miyamoto, Yuho</creatorcontrib><creatorcontrib>Ishii, Noriko</creatorcontrib><creatorcontrib>Yuri, Yukihisa</creatorcontrib><creatorcontrib>Hasegawa, Kunihiro</creatorcontrib><creatorcontrib>Nakano, Chikage</creatorcontrib><creatorcontrib>Nishimura, Takashi</creatorcontrib><creatorcontrib>Yoh, Kazunori</creatorcontrib><creatorcontrib>Aizawa, Nobuhiro</creatorcontrib><creatorcontrib>Sakai, Yoshiyuki</creatorcontrib><creatorcontrib>Ikeda, Naoto</creatorcontrib><creatorcontrib>Takashima, Tomoyuki</creatorcontrib><creatorcontrib>Takata, Ryo</creatorcontrib><creatorcontrib>Iijima, Hiroko</creatorcontrib><creatorcontrib>Nishiguchi, Shuhei</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cachexia, sarcopenia and muscle</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nishikawa, Hiroki</au><au>Enomoto, Hirayuki</au><au>Ishii, Akio</au><au>Iwata, Yoshinori</au><au>Miyamoto, Yuho</au><au>Ishii, Noriko</au><au>Yuri, Yukihisa</au><au>Hasegawa, Kunihiro</au><au>Nakano, Chikage</au><au>Nishimura, Takashi</au><au>Yoh, Kazunori</au><au>Aizawa, Nobuhiro</au><au>Sakai, Yoshiyuki</au><au>Ikeda, Naoto</au><au>Takashima, Tomoyuki</au><au>Takata, Ryo</au><au>Iijima, Hiroko</au><au>Nishiguchi, Shuhei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis</atitle><jtitle>Journal of cachexia, sarcopenia and muscle</jtitle><addtitle>J Cachexia Sarcopenia Muscle</addtitle><date>2017-12</date><risdate>2017</risdate><volume>8</volume><issue>6</issue><spage>915</spage><epage>925</epage><pages>915-925</pages><issn>2190-5991</issn><eissn>2190-6009</eissn><abstract>Background
We aimed to elucidate the relationship between serum myostatin levels and other markers including skeletal muscle mass and to investigate the influence of serum myostatin levels on survival for patients with liver cirrhosis (LC).
Methods
A total of 198 LC subjects were analysed in this study. Myostatin levels were measured using stored sera. We retrospectively investigated the relationship between myostatin level and other markers, and the influence of myostatin level on overall survival (OS). Assessment of skeletal muscle mass was performed using the psoas muscle index (PMI) on computed tomography images at baseline. PMI indicates the sum of bilateral psoas muscle mass calculated by hand tracing at the lumber three level on computed tomography images divided by height squared (cm2/m2). The study cohort was divided into two groups based on the median myostatin value in each gender.
Results
Our study cohort included 108 male and 90 female patients with a median age of 67.5 years. The median (range) myostatin level for male patients was 3419.6 pg/mL (578.4–12897.7 pg/mL), whereas that for female patients was 2662.4 pg/mL (710.4–8782.0 pg/mL) (P = 0.0024). Median (range) serum myostatin level for Child–Pugh A patients (n = 123) was 2726.0 pg/mL (578.4–12667.2 pg/mL), whereas that for Child–Pugh B or C patients (n = 75) was 3615.2 pg/mL (663.3–12897.7 pg/mL) (P = 0.0011). For the entire cohort, the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 93.94%, 72.71%, 50.37%, and 38.47%, respectively, in the high‐myostatin group and 96.97%, 83.27%, 73.60%, and 69.95%, respectively, in the low‐myostatin group (P = 0.0001). After excluding hepatocellular carcinoma patients (at baseline) from our analysis (n = 158), the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 96.0%, 77.93%, 52.97%, and 39.08%, respectively, in the high‐myostatin group and 96.39%, 87.58%, 77.63%, and 73.24%, respectively, in the low‐myostatin group (P = 0.0005). Higher age (P = 0.0111) and lower PMI (P < 0.0001) were identified as significant predictors of poorer OS in our multivariate analysis, while higher serum myostatin (P = 0.0855) tended to be a significant adverse predictor. In both genders, PMI, serum albumin, prothrombin time, and branched‐chain amino acid to tyrosine ratio showed a significantly inverse correlation with myostatin levels, and serum ammonia levels showed a significantly positive correlation with myostatin levels.
Conclusions
Higher serum myostatin levels correlated with muscle mass loss, hyperammonemia, and impaired protein synthesis, as reflected by lower serum albumin levels and lower branched‐chain amino acid to tyrosine ratio levels. High serum myostatin levels were also associated with a reduced OS rate in LC patients.</abstract><cop>Germany</cop><pub>John Wiley & Sons, Inc</pub><pmid>28627027</pmid><doi>10.1002/jcsm.12212</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2190-5991 |
| ispartof | Journal of cachexia, sarcopenia and muscle, 2017-12, Vol.8 (6), p.915-925 |
| issn | 2190-5991 2190-6009 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5700437 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Biomarkers Body mass index Cause of Death Clinical outcomes Female Humans Insulin Kaplan-Meier Estimate Liver cancer Liver cirrhosis Liver Cirrhosis - blood Liver Cirrhosis - diagnosis Liver Cirrhosis - mortality Liver diseases Male Medical prognosis Metabolic disorders Middle Aged Muscle, Skeletal - metabolism Muscle, Skeletal - pathology Musculoskeletal system Myostatin - blood NMR Nuclear magnetic resonance Original Predictor Prognosis Proportional Hazards Models Protein synthesis Proteins Retrospective Studies Sarcopenia Serum myostatin Skeletal muscle Studies Ultrasonic imaging Young Adult |
| title | Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A14%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20serum%20myostatin%20level%20is%20associated%20with%20worse%20survival%20in%20patients%20with%20liver%20cirrhosis&rft.jtitle=Journal%20of%20cachexia,%20sarcopenia%20and%20muscle&rft.au=Nishikawa,%20Hiroki&rft.date=2017-12&rft.volume=8&rft.issue=6&rft.spage=915&rft.epage=925&rft.pages=915-925&rft.issn=2190-5991&rft.eissn=2190-6009&rft_id=info:doi/10.1002/jcsm.12212&rft_dat=%3Cproquest_pubme%3E2289813310%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2289813310&rft_id=info:pmid/28627027&rfr_iscdi=true |